摘要
银屑病是一种慢性炎症性皮肤疾病,其发病机制主要与白细胞介素(IL)-23/辅助性T细胞(Th)17反应轴和IL-12/Th1反应轴相关,同时固有免疫成分也逐渐成为银屑病研究领域的新热点。临床上主要有免疫调节或抑制剂、抗炎药物、生物制剂和物理光线等治疗手段,免疫调节或抑制剂与抗炎药物已普遍应用于临床,而随着对银屑病发病机制的逐渐认识,基于不同靶点的生物制剂靶向治疗已成为主要研究热点。但不同手段之间和不同药物之间的临床疗效与不良反应均有较大差别。
Psoriasis is a chronic inflammatory skin disease, and its pathogenesis is mainly related to interleukin（ IL）- 23/Th17 and IL-12/Thl axis, at the same time, the innate immunity has gradually become a new hotspot in the research field of psoriasis. Clinically, there are mainly immunomodulators/immunosuppressors, anti-inflammatory drugs, biological agents and physical light therapies for psoriasis, while the first two have been widely applied to clinical practice, along with our gradual understanding of its pathogenesis, targeted therapies of biological agents towards different targets have become the focus of the research. But the clinical efficacy and adverse reactions between different methods or different drugs are significantly different.
出处
《医学综述》
2017年第23期4659-4664,4670,共7页
Medical Recapitulate
基金
国家级大学生创新训练计划(201510055112)
关键词
银屑病
免疫抑制剂
生物制剂
Psoriasis
Immunosuppressive agents
Biological agents
